Insider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) Insider Sells $22,624.28 in Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) insider Bryan Ball sold 6,596 shares of the stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $3.43, for a total transaction of $22,624.28. Following the completion of the transaction, the insider owned 515,955 shares in the company, valued at $1,769,725.65. The trade was a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bryan Ball also recently made the following trade(s):

• On Tuesday, April 14th, Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.64, for a total transaction of $336,554.40.
• On Monday, April 13th, Bryan Ball sold 26,389 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.46, for a total transaction of $91,305.94.
• On Thursday, April 9th, Bryan Ball sold 50,000 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.57, for a total transaction of $178,500.00.
• On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total transaction of $6,070.54.

Whitehawk Therapeutics Trading Down 2.5%

WHWK opened at $3.90 on Thursday. Whitehawk Therapeutics, Inc. has a 1-year low of $1.39 and a 1-year high of $4.48. The company has a market capitalization of $184.07 million, a PE ratio of 8.30 and a beta of 0.57. The firm’s 50 day simple moving average is $3.40 and its two-hundred day simple moving average is $2.76.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.21.

Analyst Upgrades and Downgrades

Several analysts have recently commented on WHWK shares. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. JonesTrading started coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price objective on the stock. Wall Street Zen downgraded shares of Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Oppenheimer started coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.50.

Hedge Funds Weigh In On Whitehawk Therapeutics

Several institutional investors have recently bought and sold shares of WHWK. Vanguard Group Inc. purchased a new position in Whitehawk Therapeutics during the third quarter valued at $2,552,000. Peapod Lane Capital LLC purchased a new position in Whitehawk Therapeutics during the third quarter valued at $577,000. Dimensional Fund Advisors LP purchased a new position in Whitehawk Therapeutics during the third quarter valued at $84,000. Avoro Capital Advisors LLC purchased a new position in Whitehawk Therapeutics during the third quarter valued at $5,414,000. Finally, Suvretta Capital Management LLC purchased a new position in Whitehawk Therapeutics during the third quarter valued at $7,030,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.